Obinutuzumab in patients with Sjogren's disease immunised against rituximab

Ann Rheum Dis. 2024 Feb 15;83(3):407-408. doi: 10.1136/ard-2023-224999.

Authors

Mathilde Pezot¹, Gaétane Nocturne¹, Rakiba Belkhir¹, Julien Henry¹, Stephan Pavy¹, Raphaèle Seror¹, Xavier Mariette¹, Samuel Bitoun²

Affiliations

¹ Rheumatology Department, Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, FHU CARE, INSERM UMR1184, Le Kremlin Bicêtre, France.
² Rheumatology Department, Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, FHU CARE, INSERM UMR1184, Le Kremlin Bicêtre, France samuel.bitoun@aphp.fr.

PMID: 37945315
DOI: 10.1136/ard-2023-224999

No abstract available

Keywords: Autoimmune Diseases; Connective Tissue Diseases; Rituximab; Sjogren's Syndrome.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Humans
Rituximab / therapeutic use
Sjogren's Syndrome* / drug therapy

Substances

Rituximab
obinutuzumab
Antibodies, Monoclonal, Humanized